Evaluation of Some Proteins as Potential Markers in Different Durations of Diabetic Patients Type 2

Authors

Sarah Sameer Sami Department of Clinical Laboratory Sciences, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq. Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq. https://orcid.org/0009-0009-4707-9063
Ekhlass M. Taha Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq. https://orcid.org/0000-0002-6866-8600

DOI:

https://doi.org/10.30526/38.4.3656

Keywords:

Laminin subunit alpha 2, Mixed lineage leukemia 4, Plexin domain containing 2, Protein Z, Type 2 diabetes

Abstract

Type 2 diabetic mellitus (T2DM) is growing rapidly around the world, due in large part to significant changes in the modern human lifestyle. T2DM and its complications are affected by a complex interplay of genetic, life course, ecological, cultural, socioeconomic, cognitive-psychological-behavioral, and access to care factors that influence regional variations in disease burden and care quality by gender. This study aims to investigate the role of laminin subunit alpha 2 (LAMA2), mixed lineage leukemia 4 (MLL4), plexin domain containing 2 (PLXDC2), and Protein Z (PORZ) as potential biomarkers for T2DM at different durations of the disease. These biomarkers were assessed using an enzyme-linked immunosorbent assay. While biochemical parameters (FSG) and lipid profiles were measured spectrophotometrically. HbA1C using HPLC. The volunteer individuals were subdivided into five groups: group I: DM with duration of disease less than 1 year, group II: DM with duration of disease from 1-5 years, group III: DM with duration of disease from 5-10 years, group IV: DM with duration of disease more than 10 years, group V: healthy control. Results showed a significant difference among the studied groups in LAMA2 and PLXDC2. In contrast, no significant difference was observed in MLL4 and POR Z. It has been concluded that LAMA2 and PLXDC2 are involved in the duration of the disease

Author Biographies

Sarah Sameer Sami, Department of Clinical Laboratory Sciences, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq. Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.

¹Department of Clinical Laboratory Sciences, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq.

²Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.
Ekhlass M. Taha, Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.

Department of Chemistry, College of Science for Women, University of Baghdad, Baghdad, Iraq.

References

1. Chen X, Merovci A, DeFronzo RA, Tripathy D. Chronic physiologic hyperglycemia impairs insulin-mediated suppression of plasma glucagon concentration in healthy humans. Metabolism. 2023; 142: 155512. https://doi.org/10.1016/j.metabol.2023.155512.

2. Patel MK, Ramachandran A, Babulal MK, Vasanthi RK. Will hyperglycemia influence the cardiorespiratory endurance and other determinants among community-dwelling type 2 Dm patients? A cross-sectional study. JPSP 2022; 6(4):10403-10408.

3. Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, Yazdi H, Booker L. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007; 78(3):305-312. https://doi.org/10.1016/j.diabres.2007.05.004.

4. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999; 48(5):643-648. https://doi.org/10.1046/j.1365-2125.1999.00092.x.

5. Bellary S, Kyrou I, Brown JE, Bailey CJ. Type 2 diabetes mellitus in older adults: Clinical considerations and management. Nat Rev Endocrinol. 2021; 17(9):534-548. https://doi.org/10.1038/s41574-021-00474-4.

6. Ergashev UY, Ernazarov KI, Zohirov AR, Alzabni ID. Complex treatment of experimental model of diabetic foot syndrome. Am J Med Sci. 2022; 12(4):471-480. https://doi.org/10.5923/j.ajmms.20221204.02.

7. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2021; 44(S1): S1-S232. https://doi.org/10.2337/dc21-S001.

8. Rafiqovich ZA. Study of the effect of lipid peroxidase analysis on the body in diabetic foot syndrome. Conferencea. 2023; 76-82. https://conferencea.org/index.php/conferences/article/view/1990.

9. Ergashev UY, Zokhirov AR, Minavarkhujaev RR. Study and treatment of changes in biochemical processes in complications of diabetes mellitus. 2023.

10. Ogurtsova K, Guariguata L, Barengo NC, Ruiz PLD, Sacre JW. IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract. 2022; 183:109118. https://doi.org/10.1016/j.diabres.2022.109118.

11. Broze GJ, Miletich JP. Human protein Z. J Clin Invest. 1984; 73(3):933-938. https://doi.org/10.1172/JCI111987.

12. Kaiafa G, Veneti S, Polychronopoulos G, Pilalas D, Daios S, Kanellos I. Is HbA1c an ideal biomarker of well-controlled Diabetes? Postgrad Med J. 2021; 97(1148):380-383. https://doi.org/10.1136/postgradmedj-2020-137861.

13. Takahashi E, Okumura A, Unoki-Kubota H, Hirano H, Kasuga M. Differential proteome analysis of serum proteins associated with the development of type 2 diabetes mellitus in the KK-A(y) mouse model using the iTRAQ technique. J Proteomics. 2013; 84:40–51. https://doi.org/10.1016/j.jprot.2013.03.014.

14. Scoville DW, Cyphert HA, Liao L, Xu J, Reynolds A, Guo S. MLL3 and MLL4 methyltransferases bind to the MAFA and MAFB transcription factors to regulate islet beta-cell function. Diabetes. 2015; 64(10):3772–3783. https://doi.org/10.2337/db15-0281.

15. Miller-Delaney SF, Lieberam I, Murphy P, Mitchell KJ. Plxdc2 is a mitogen for neural progenitors. PLOS One. 2011; 6(1):e14565. https://doi.org/10.1371/journal.pone.0014565.

16. Daniel WW. Biostatistics: A foundation for analysis in the health sciences. Wiley; 2018, 11th ed.

17. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982; 28(10):2077-2080. PMID: 6812986.

18. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014; 371(15):1392-1406. https://doi.org/10.1056/NEJMoa1407963.

19. Alicic RZ, Neumiller JJ. Incretin therapies for patients with type 2 diabetes and chronic kidney disease. J Clin Med. 2023; 13(1):201. https://doi.org/10.3390/jcm13010201.

20. Guo F, Moellering DR, Garvey WT. Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. Metab Syndr Relat Disord. 2014; 12(5):258-268. https://doi.org/10.1089/met.2013.0128.

21. Palladino R, Tabak AG, Khunti K, Valabhji J, Majeed A, Millett C, Vamos EP. Association between pre-diabetes and microvascular and macrovascular disease in newly diagnosed type 2 diabetes. BMJ Open Diabetes Res Care. 2020; 8(1):e001061. https://doi.org/10.1136/bmjdrc-2020-001061.

22. Hopp A, Jones K, Meng H, Ott E, Basuni N, Axon SP. 184 Defining the pathological natural history of LAMA2 muscular dystrophy. Neuromuscul Dis. 2022; 32(1):S121-S121. https://doi.org/10.1016/j.nmd.2022.07.327.

23. Sadiq CH, Hussein RH, Maulood IM. Ghrelin and leptin and their relations with insulin resistance in diabetes mellitus type 2 patients. Baghdad Sci J. 2022; 19(1):33-42. https://doi.org/10.21123/bsj.2022.19.1.0033.

24. Espeland MA, Lipska K, Miller ME, Rushing J, Cohen RA, Verghese J, McDermott MM, King AC, Strotmeyer ES, Blair SN, Pahor M, Reid K, Demons J, Kritchevsky SB; LIFE Study Investigators. Effects of physical activity intervention on physical and cognitive function in sedentary adults with and without diabetes. J Gerontol A Biol Sci Med Sci. 2017; 72(6):861-866. https://doi.org/10.1093/gerona/glw179.

25. Triggle CR, Mohammed I, Bshesh K, Marei I, Ye K, Ding H, MacDonald R, Hollenberg MD. Metformin: Is it a drug for all reasons and diseases? Metabolism. 2022; 133:155223. https://doi.org/10.1016/j.metabol.2022.155223.

26. Mohammed SK, Taha EM, Muhi SA. A case-control study to determination FBXW7 and fetuin-A levels in patients with type 2 diabetes in Iraq. J Diabetes Metab Disord. 2021; 20(1):237-243. https://doi.org/10.1007/s40200-021-00738-x.

27. American Diabetes Association. 5. Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41(Suppl 1):S51-S54. https://doi.org/10.2337/dc18-S005.

28. Bouman K, Gubbels M, van den Heuvel FMA, Groothuis JT, Erasmus CE, Nijveldt R, Udink Ten Cate FEA, Voermans NC. Cardiac involvement in two rare neuromuscular diseases: LAMA2-related muscular dystrophy and SELENON-related myopathy. Neuromuscul Disord. 2022; 32(8):635-642. https://doi.org/ 10.1016/j.nmd.2022.06.004.

29. Santacroce R, Sarno M, Cappucci F, Sessa F, Colaizzo D, Brancaccio V, Grandone E, Margaglione M. Low protein Z levels and risk of occurrence of deep vein thrombosis. J Thromb Haemost. 2006; 4(11):2417-2422. https://doi.org/10.1111/j.1538-7836.2006.02186.x.

Downloads

Published

20-Oct-2025

Issue

Vol. 38 No. 4 (2025)

Section

Chemistry

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

licenseTerms

How to Cite

[1]

Sami, S.S. and Taha , E.M. 2025. Evaluation of Some Proteins as Potential Markers in Different Durations of Diabetic Patients Type 2 . Ibn AL-Haitham Journal For Pure and Applied Sciences. 38, 4 (Oct. 2025), 230–236. DOI:https://doi.org/10.30526/38.4.3656.